BRAF and ganglioglioma: To our knowledge, this is the first case of an adult with progressive BRAF V600E-mutated spinal ganglioglioma successfully treated with vemurafenib as a single agent and with ongoing and prolonged stable residual disease 21 months after vemurafenib discontinuation.